{"disease":{"id":"monoclonal-gammopathy-of-undetermined-significance-mgus","name":"monoclonal gammopathy of undetermined significance mgus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06690593","title":"Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy","phase":"","overall_status":"RECRUITING","enrollment_count":2990,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT05283993","title":"A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06140524","title":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03951220","title":"The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Oxford University Hospitals NHS Trust","has_results":true},{"nct_id":"NCT07214324","title":"Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Azienda USL Reggio Emilia - IRCCS","has_results":false},{"nct_id":"NCT07057583","title":"A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}